One of the key facts around the genomics industry in the past five years was an enormous valuation bubble around 2021.
One example is GeneDx (briefly called Sema4). If you had invested just $250 a year ago, it would be worth $16,000 today.
Today, October 30, 2024 the share price is $82 with a market cap of $2.2B.
In November 2020, it was around $300.
On February 7, 2021, it was $851.
It was $1.27 on November 5, 2023, almost exactly a year ago.
Today', it's $82, or up around 65X in one year.
See an October 29, 2024, interview with CEO Katherine Stueland here.
See a 12/2024 article in ENDPOINTS here.
###
It can be hard to find share price histories of no-longer-traded firms, but by memory, Invitae (NVTA) ran about $15 in 2019/2020, rose to around $60 in 2021 (although it had no COVID business), and fell to single digits then zero during 2023 and into early 2024.
You'd also see a "Covid valuation bubble" at Castle CSTL, running about $30 before the pandemic, $95 in early 2021, falling to $12 a year or two later and around $30 today.
